According to him, a complex of this kind is the only one in the CIS. $ 42 million was invested in the construction. There is a pharmaceutical plant, a centre of research, development, and technology, a laboratory, raw material stores and finished product storages and a power-supply system site in the territory of 5 hectares.
The German partners from the engineering company “Linde Engineering” helped to design the “Biopharma” plant. The complex itself was built at a record pace – within a year and three months.
In the nearest time, construction of the third stage of the research and production complex – a blood plasma plant – should be completed. It will produce drugs for the treatment of immunodeficiency diseases – immunoglobulin, albumin, bioven.
At the moment, “Biopharma” has become a top performer in the domestic market of Ukraine and is developing new markets – in particular, in Asia, Africa and the Middle East. Recently, the delegation of “Biopharma” has visited the countries of South America – Argentina, Chile, Ecuador, Peru and Bolivia.
“The Latin American market is very promising. It is developing rapidly, and it is necessary to establish cooperation with it,” Vasyl Khmelnytsky said.